ArticleTranslational psychiatry2026
From brain networks to peripheral signatures: candidate biomarkers for major depressive disorder.
Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is a leading cause of disability worldwide, yet its neural basis and biomarkers remain elusive. In this study, we combined neuroimaging, transcriptomics, proteomics, and machine learning to bridge large-scale brain network dysfunction with peripheral molecular signatures. Resting-state functional magnetic resonance imaging (fMRI) from 544 MDD patients and 569 healthy controls (HC) revealed altered network topology involving thalamic, fronto-striatal, and parietal regions. Connectome-transcriptomic association analysis of these network alterations, in conjunction with differential gene expression analysis, identified 24 candidate genes, with FKBP5, PTX3, and APCDD1 prioritized by machine learning. Plasma proteomics further validated altered protein expression of the three prioritized genes in two independent cohorts (adults: 162 MDD patients and 103 HC; adolescents: 71 MDD patients and 39 HC). Protein-based diagnostic models achieved accuracies of 69.6% in adults and 83.1% in adolescents, while protein levels were significantly higher in adolescents with MDD than in HC (all P < 0.05). These findings suggest that PTX3, APCDD1, and FKBP5 may serve as candidate peripheral biomarkers associated with MDD-related brain network alterations.
Indexed as
Identifiers
42918767What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.